Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study.

ABSTRACT:

Background

Cladribine (CLAD) stands as an oral disease modifying treatment (DMT) for multiple sclerosis (MS) patients, distinguished by its unique dosing regimen and mechanism of action. However, real-world data on its effectiveness remain limited, particularly regarding the clinical and therapeutical management beyond the 2-year treatment schedule.

Objectives

The aim of our study was to explore the effectiveness profile of CLAD in individuals with MS (pwMS). We assessed the proportion of patients achieving no evidence of disease activity (NEDA-3) status and identified variables associated with better outcomes.

Design

In this retrospective study, we collected clinical and magnetic resonance imaging (MRI) data of MS patients across 10 MS Clinics in Central Italy who st

SUBMITTER: Lucchini M 

PROVIDER: S-EPMC12745522 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature